Literature DB >> 20491793

Failure of regulation results in an amplified oxidation burst by neutrophils in children with primary nephrotic syndrome.

R Bertelli1, A Trivelli, A Magnasco, M Cioni, M Bodria, A Carrea, G Montobbio, G Barbano, G M Ghiggeri.   

Abstract

The mechanism responsible for proteinuria in non-genetic idiopathic nephrotic syndrome (iNS) is unknown. Animal models suggest an effect of free radicals on podocytes, and indirect evidence in humans confirm this implication. We determined the oxidative burst by blood CD15+ polymorphonucleates (PMN) utilizing the 5-(and-6)-carboxy-2',7'-dichlorofluorescin diacetate (DCF-DA) fluorescence assay in 38 children with iNS. Results were compared with PMN from normal subjects and patients with renal pathologies considered traditionally to be models of oxidative stress [six anti-neutrophil cytoplasmic autoantibody (ANCA) vasculitis, seven post-infectious glomerulonephritis]. Radicals of oxygen (ROS) production was finally determined in a patient with immunodeficiency, polyendocrinopathy, enteropathy X-linked (IPEX) and in seven iNS children after treatment with Rituximab. Results demonstrated a 10-fold increase of ROS production by resting PMN in iNS compared to normal PMN. When PMN were separated from other cells, ROS increased significantly in all conditions while a near-normal production was restored by adding autologous cells and/or supernatants in controls, vasculitis and post-infectious glomerulonephritis but not in iNS. Results indicated that the oxidative burst was regulated by soluble factors and that this regulatory circuit was altered in iNS. PMN obtained from a child with IPEX produced 100 times more ROS during exacerbation of clinical symptoms and restored to a near normal-level in remission. Rituximab decreased ROS production by 60%. In conclusion, our study shows that oxidant production is increased in iNS for an imbalance between PMN and other blood cells. Regulatory T cells (Tregs) and CD20 are probably involved in this regulation. Overall, our observations reinforce the concept that oxidants deriving from PMN are implicated in iNS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20491793      PMCID: PMC2940160          DOI: 10.1111/j.1365-2249.2010.04160.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  39 in total

Review 1.  Role of reactive oxygen metabolites in experimental glomerular disease.

Authors:  S V Shah
Journal:  Kidney Int       Date:  1989-05       Impact factor: 10.612

2.  Letter: Lymphokines and nephrotic syndrome.

Authors:  G Lagrue; S Xheneumont; A Branellec; B Weil
Journal:  Lancet       Date:  1975-02-01       Impact factor: 79.321

3.  Renal purine efflux and xanthine oxidase activity during experimental nephrosis in rats: difference between puromycin aminonucleoside and adriamycin nephrosis.

Authors:  F Ginevri; R Gusmano; R Oleggini; S Acerbo; R Bertelli; F Perfumo; G Cercignani; S Allegrini; F D'Allegri; G Ghiggeri
Journal:  Clin Sci (Lond)       Date:  1990-03       Impact factor: 6.124

4.  Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro.

Authors:  R J Falk; R S Terrell; L A Charles; J C Jennette
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

5.  Puromycin aminonucleoside metabolism by glomeruli and glomerular epithelial cells in vitro.

Authors:  G M Ghiggeri; G Cercignani; F Ginevri; R Bertelli; L Zetta; F Greco; G Candiano; A Trivelli; R Gusmano
Journal:  Kidney Int       Date:  1991-07       Impact factor: 10.612

6.  Primary nephrotic syndrome in children: clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. A Report of the International Study of Kidney Disease in Children.

Authors: 
Journal:  Kidney Int       Date:  1981-12       Impact factor: 10.612

7.  Adriamycin-induced glomerulosclerosis in the rat.

Authors:  T Bertani; G Rocchi; G Sacchi; G Mecca; G Remuzzi
Journal:  Am J Kidney Dis       Date:  1986-01       Impact factor: 8.860

8.  Adriamycin-induced nephrotic syndrome in rats: sequence of pathologic events.

Authors:  T Bertani; A Poggi; R Pozzoni; F Delaini; G Sacchi; Y Thoua; G Mecca; G Remuzzi; M B Donati
Journal:  Lab Invest       Date:  1982-01       Impact factor: 5.662

9.  Peroxidative damage of the erythrocyte membrane in children with nephrotic syndrome.

Authors:  F Ginevri; G M Ghiggeri; G Candiano; R Oleggini; R Bertelli; M T Piccardo; F Perfumo; R Gusmano
Journal:  Pediatr Nephrol       Date:  1989-01       Impact factor: 3.714

Review 10.  Familial forms of nephrotic syndrome.

Authors:  Gianluca Caridi; Antonella Trivelli; Simone Sanna-Cherchi; Francesco Perfumo; Gian Marco Ghiggeri
Journal:  Pediatr Nephrol       Date:  2008-12-09       Impact factor: 3.714

View more
  14 in total

1.  Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial.

Authors:  Pietro Ravani; Alberto Magnasco; Alberto Edefonti; Luisa Murer; Rossella Rossi; Luciana Ghio; Elisa Benetti; Floriana Scozzola; Andrea Pasini; Nadia Dallera; Felice Sica; Mirco Belingheri; Francesco Scolari; Gian Marco Ghiggeri
Journal:  Clin J Am Soc Nephrol       Date:  2011-05-12       Impact factor: 8.237

Review 2.  Pathogenesis of childhood idiopathic nephrotic syndrome: a paradigm shift from T-cells to podocytes.

Authors:  Kazunari Kaneko; Shoji Tsuji; Takahisa Kimata; Tetsuya Kitao; Sohsaku Yamanouchi; Shogo Kato
Journal:  World J Pediatr       Date:  2015-01-28       Impact factor: 2.764

Review 3.  Genetics of childhood steroid-sensitive nephrotic syndrome.

Authors:  Alana M Karp; Rasheed A Gbadegesin
Journal:  Pediatr Nephrol       Date:  2016-07-29       Impact factor: 3.714

Review 4.  Regulatory T cells and minimal change nephropathy: in the midst of a complex network.

Authors:  R Bertelli; A Bonanni; A Di Donato; M Cioni; P Ravani; G M Ghiggeri
Journal:  Clin Exp Immunol       Date:  2015-10-12       Impact factor: 4.330

5.  Regulation of innate immunity by the nucleotide pathway in children with idiopathic nephrotic syndrome.

Authors:  R Bertelli; M Bodria; M Nobile; S Alloisio; R Barbieri; G Montobbio; P Patrone; G M Ghiggeri
Journal:  Clin Exp Immunol       Date:  2011-07-15       Impact factor: 4.330

6.  Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial.

Authors:  Pietro Ravani; Roberta Rossi; Alice Bonanni; Robert R Quinn; Felice Sica; Monica Bodria; Andrea Pasini; Giovanni Montini; Alberto Edefonti; Mirco Belingheri; Donatella De Giovanni; Giancarlo Barbano; Ludovica Degl'Innocenti; Francesco Scolari; Luisa Murer; Jochen Reiser; Alessia Fornoni; Gian Marco Ghiggeri
Journal:  J Am Soc Nephrol       Date:  2015-01-15       Impact factor: 10.121

Review 7.  Rituximab therapy in nephrotic syndrome: implications for patients' management.

Authors:  Aditi Sinha; Arvind Bagga
Journal:  Nat Rev Nephrol       Date:  2013-01-22       Impact factor: 28.314

8.  Rituximab in children with resistant idiopathic nephrotic syndrome.

Authors:  Alberto Magnasco; Pietro Ravani; Alberto Edefonti; Luisa Murer; Luciana Ghio; Mirco Belingheri; Elisa Benetti; Corrado Murtas; Giovanni Messina; Laura Massella; Maria Gabriella Porcellini; Michela Montagna; Mario Regazzi; Francesco Scolari; Gian Marco Ghiggeri
Journal:  J Am Soc Nephrol       Date:  2012-05-10       Impact factor: 10.121

9.  Nephrotic syndrome in children: from bench to treatment.

Authors:  J-C Davin; N W Rutjes
Journal:  Int J Nephrol       Date:  2011-08-28

10.  Increased Migratory and Activation Cell Markers of Peripheral Blood Lymphocytes in an Experimental Model of Nephrotic Syndrome.

Authors:  Wagner de Fátima Pereira; Gustavo Eustáquio Alvim Brito-Melo; Cláudia Martins Carneiro; Dirceu de Sousa Melo; Karine Beatriz Costa; Fábio Lourenço Tadeu Guimarães; Etel Rocha-Vieira; Érica Leandro Marciano Vieira; Ana Cristina Simões e Silva
Journal:  Mediators Inflamm       Date:  2015-05-07       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.